Palo-Negro-Blog: Johnson & Johnson

Showing posts with label Johnson & Johnson. Show all posts

Tuesday, August 30, 2016

Johnson & Johnson to Participate in the 2016 Wells Fargo 11th Annual Healthcare Conference

http://www.jnj.com/news/all/Johnson-Johnson-to-Participate-in-the-2016-Wells-Fargo-11th-Annual-Healthcare-Conference

Ethicon Announces Strategic Collaboration With Touch Surgery to Evolve Medical Education

Somerville, NJ, August 22, 2016 -- Ethicon, Inc., part of the Johnson & Johnson Medical Devices Companies, announces a strategic collaboration with Touch Surgery to help improve patient outcomes by delivering simulated surgical training based on the safe and efficacious use of Ethicon products in a free mobile app that can reach medical professionals in even remote regions of the world.

http://www.jnj.com/news/all/Ethicon-Announces-Strategic-Collaboration-With-Touch-Surgery-to-Evolve-Medical-Education

For U.S. Media Only: Janssen Announces 25 Presentations at Upcoming ESC Congress 2016, Including New Clinical and Real-World Research on XARELTO® and Latest Findings from REVISIT-US

RARITAN, NJ (August 22, 2016) – Janssen Pharmaceuticals, Inc., today announced that 25 abstracts have been accepted for presentation by Janssen and its development partner, Bayer, at the ESC Congress 2016, taking place August 27-31 in Rome, Italy. New real-world evidence from the EXPLORER research program, including latest findings from the REVISIT-US study, will address how XARELTO® (rivaroxaban), a non-vitamin K antagonist oral anticoagulant (NOAC), is performing in routine clinical practice. Also, the companies will unveil the design of the GALILEO trial, which seeks to address blood clot prevention for patients following successful transcatheter aortic valve replacement (TAVR).

http://www.jnj.com/news/all/Janssen-Announces-25-Presentations-at-Upcoming-ESC-Congress-2016-Including-New-Clinical-and-Real-World-Research-on-XARELTO-and-Latest-Findings-from-REVISIT-US